GSK Awarded $63 Million US Government Contract for Pandemic Vaccine Research
GlaxoSmithKline (London, UK, www.gsk.com) has been awarded a $63.3-million contract from the US Department of Health and Human Services (HHS) for the development of pre-pandemic and pandemic flu vaccines.
GlaxoSmithKline (London, UK, www.gsk.com) has been awarded a $63.3-million contract from the US Department of Health and Human Services (HHS) for the development of pre-pandemic and pandemic flu vaccines. The contract supports GSK’s ongoing pandemic vaccine research studying the use of the company’s adjuvant technology in combination with antigens to induce a strong immune response.
Under the terms of the contract, GSK will engage in research and development leading to licensure of antigen-sparing pre-pandemic and pandemic vaccines with adjuvant that will help the US government extend the limited North American supply of pandemic flu vaccines to protect larger populations in the event of a flu pandemic. The five-year contract also gives the government the option to fund an additional $44 million of future clinical development programs related to antigen-sparing pandemic vaccines.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
